Liposomal doxorubicin received FDA approval for use in combination with bortezomib in patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy.
Kun He, PhD
Advertisement
Articles by Kun He, PhD
Advertisement
Latest Updated Articles
- Liposomal Doxorubicin in Combination With Bortezomib for Relapsed or Refractory Multiple Myeloma
Published: November 1st 2007 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
FDA Approves Revumenib in R/R NPM1-Mutant AML
3
Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment
4
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
5
